|Videos|February 4, 2021
Tarsus execs discuss origins, treating Demodex blepharitis
Author(s)OT Staff Reports
Tarsus Pharmaceuticals's CEO Bobby Azamian, MD, PhD, and Chairman Michael Ackermann, PhD, speak on the development of their company and the latest updates on their lead candidate product to treat Demodex blepharitis.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
STAAR and Broadwood conflict over proposed Alcon merger continues
2
FDA clears IND for Complement Therapeutics’ CTx001 gene therapy in geographic atrophy
3
Ocular surface: Targeted therapies for a multifactorial problem
4
Increasing the knowledge base of GA is key to individualizing patient therapy
5